Gulf War Illness Innovative Treatment Evaluation Award | Apply Online

Opportunity Summary:

The Gulf War Illness Innovative Treatment Evaluation Award (ITEA) is a Department of Defense Gulf War Illness Research Program funding opportunity meant to jump start early clinical testing of promising treatments for Gulf War Illness (GWI) specifically in veterans who served in the 1990 to 1991 Gulf War. The core purpose is to fund small, early phase, proof-of-principle clinical trials (Phase 0, Phase I, or Phase I/II), including studies of medical devices across FDA Classes I through III. The program is built for interventions that are still at an initial testing stage in this population, and it is explicitly designed so applicants do not need preliminary data in a GWI model system to apply. Instead, the application needs to make a strong, scientifically sound case based on reasoning and a critical reading of existing literature. The expectation is that results from an ITEA study will generate credible early clinical signals (safety, feasibility, and early effectiveness/biologic activity) that justify and inform larger, later-phase efficacy trials or a clearer path toward implementation.

A major emphasis is innovation, but innovation is defined broadly. A proposal can be innovative by testing something truly new for GWI, or by taking an intervention that has been explored for related chronic multisymptom conditions (such as fibromyalgia or chronic fatigue syndrome) and evaluating it for the first time in Gulf War veterans with GWI. What matters is that the trial is centered on GWI and this specific veteran cohort, rather than using GWI as a side note to another disease area. At the same time, the program draws a line against projects that are already far along: if an intervention has extensive preliminary and preclinical development suggesting it is already well established for GWI, the application may be considered less aligned with the ITEA intent, since the mechanism is meant for earlier, more exploratory clinical evaluation.

The scope of allowable interventions is intentionally wide and includes pharmacologic therapies, physiologic and rehabilitative approaches, and conventional, complementary, and alternative strategies, as long as they are tested as prospective clinical trials. The solicitation allows a range of designs appropriate for early evaluation, such as systematic case series, prospective outcome evaluations, small randomized trials, or other creative prospective methods. Regardless of design, if human participants are prospectively accrued and an intervention is tested for measurable outcomes, the work is treated as a clinical trial under this program. Preclinical-only studies are not allowed under this award mechanism.

The outcomes the program cares about reflect the multisystem nature of GWI. Applicants are encouraged to measure changes in global health indicators (including biomarkers) and/or functional status, and to track improvements across symptom domains common in GWI, such as cognitive problems, pain and musculoskeletal symptoms, gastrointestinal issues, fatigue, respiratory complaints, skin problems, and sleep difficulties. The announcement also highlights interest in studies that examine GWI subgroups defined by symptom patterns or other clinical characteristics, and in interventions tied to biological alterations observed in veterans with GWI. In addition, partnerships with biotechnology or pharmaceutical companies are encouraged when they can speed development, strengthen manufacturing and regulatory readiness, or otherwise accelerate real-world availability of successful interventions.

There are clear topic boundaries. Projects focused primarily on psychiatric treatment, including PTSD, are not eligible for funding under this announcement. Separately, while Gulf War veterans have higher rates of ALS than non-deployed veterans, the program will not accept ALS-focused proposals; however, veterans with ALS may be included if the study is truly about GWI symptomatology and ALS is included within the chosen GWI case definition used for enrollment.

A key application requirement is precise, defensible participant definition. Applicants must specify how GWI cases (and any targeted subgroups) will be defined and must use a published GWI case definition that reflects GWI as a multisymptom illness. The opportunity points applicants to major reference sources discussing case definitions and the evidence base, including the Research Advisory Committee on Gulf War Veterans Illnesses 2014 report and an Institute of Medicine report on reexamined case definitions, signaling that reviewers will expect thoughtful alignment with accepted definitions and prior recommendations.

Because these awards fund interventional human research, the submission expectations look like those of a well prepared clinical development package. Proposed trials are expected to start relatively quickly: within 12 months of the award date, or within 18 months for FDA-regulated studies. Applications are expected to identify the pathobiological mechanism being targeted, define clear endpoints, follow Good Clinical Practice principles, and include a statistical analysis plan with power and sample size justification capable of answering the study objectives. They must also include a data management plan, safety management plan, and clinical monitoring plan, plus staffing support such as a study coordinator to shepherd IRB and other regulatory approvals and manage multi-site coordination and participant accrual.

Regulatory readiness is treated as a serious obligation. If the trial uses a drug not FDA-approved for the proposed investigational use, the applicant must show that an Investigational New Drug (IND) application will be submitted within 60 days of award (or that the study qualifies for an exemption consistent with the relevant regulations). If the product is a device, an Investigational Device Exemption (IDE) submission within 60 days (or evidence the device is IDE-exempt) is required. The government reserves the right to withdraw funding if the IND/IDE is not submitted within 60 days of the award date or if documented status is not obtained within six months, which effectively means applicants need a realistic regulatory plan and the ability to execute quickly.

Applicants also need to show they can recruit the right population. The solicitation requires a demonstration of access to a suitable Gulf War veteran cohort sufficient to produce meaningful results, along with a plan for meeting accrual goals and addressing how standards of care could affect enrollment. Collaboration with investigators who have established access to ill and healthy Gulf War veteran populations, particularly within the VA, is encouraged. Applicants must also document access to the intervention itself (drug, compound, device, or other materials) and show product quality consistent with applicable FDA manufacturing expectations (for example, GMP or Quality System Regulation, as appropriate to product type and stage).

Finally, the program is structured to push projects beyond a one-off pilot. The application must include a Transition Plan describing how, if the trial is successful, the intervention will move to the next phase of clinical testing and/or toward delivery to market, including prospective funding and resource pathways. Institutional support is expected to be strong and clearly evidenced, and applicants must commit to registering the trial on ClinicalTrials.gov.

From the posted opportunity details: this was a discretionary DoD Army (USAMRAA) funding opportunity (Funding Opportunity Number W81XWH-14-GWIRP-ITEA2) offered as a cooperative agreement or grant under CFDA 12.420 (Military Medical Research and Development). It anticipated about three awards with an estimated total of $2.1 million, had no cost sharing requirement, was posted September 4, 2014, and closed January 27, 2015 (archived February 26, 2015). Eligibility was listed as unrestricted, meaning any entity type could apply as long as they met the specific requirements described in the announcement.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Rural Health Care Services Outreach Program

Previous opportunity: Partnering for Preservation Technology

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 14 GWIRP ITEA2

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 14 GWIRP ITEA2) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 14 GWIRP ITEA2", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.